Brookline Maintains $310 Stock PT on Moderna, Cites Spikevax Vaccine Approvals

Key Points

*

Brookline Capital Markets reiterates its $310 price target on Moderna.

*

The firm cites the recent approvals of Spikevax in Australia, Canada, and the EU as key factors in its decision.

*

Brookline believes Moderna's strong pipeline of mRNA vaccines and therapies positions the company for long-term growth.

Overview

On August 10, 2023, Brookline Capital Markets maintained its $310 price target on Moderna (MRNA). The firm's analysts believe that the recent approvals of the company's Spikevax vaccine in Australia, Canada, and the EU are a major positive catalyst for the stock.

Spikevax is a mRNA vaccine that is designed to protect against COVID-19. It was developed by Moderna and is currently approved for use in over 70 countries. The vaccine has been shown to be safe and effective in preventing COVID-19, and it is expected to play a major role in the fight against the pandemic.

Brookline's Analysis

Brookline's analysts believe that the recent approvals of Spikevax are a major positive for Moderna. They note that the vaccine has been shown to be safe and effective, and they believe that it will be in high demand as the world continues to fight the COVID-19 pandemic.

In addition to Spikevax, Moderna has a strong pipeline of mRNA vaccines and therapies. The company is developing vaccines for a variety of diseases, including cancer, HIV, and malaria. Brookline's analysts believe that Moderna's pipeline has the potential to drive significant growth for the company in the years to come.

Risks

As with any investment, there are some risks associated with investing in Moderna. These risks include:

The risk that the COVID-19 pandemic may not continue, which could reduce demand for Spikevax.

The risk that Moderna's other vaccine and therapy candidates may not be successful.

The risk that Moderna may face competition from other companies developing mRNA vaccines and therapies.

However, Brookline's analysts believe that the potential rewards of investing in Moderna outweigh the risks. They believe that the company's strong pipeline of mRNA vaccines and therapies positions it for long-term growth.

Recommendation

Brookline Capital Markets reiterates its $310 price target on Moderna. The firm's analysts believe that the recent approvals of Spikevax are a major positive for the stock, and they believe that Moderna's strong pipeline of mRNA vaccines and therapies positions the company for long-term growth.

Investors should be aware of the risks associated with investing in Moderna. However, Brookline's analysts believe that the potential rewards of investing in the company outweigh the risks.